RS72404A - Microorganism for genetic therapeutic treatment of proliferative diseases - Google Patents
Microorganism for genetic therapeutic treatment of proliferative diseasesInfo
- Publication number
- RS72404A RS72404A YU72404A YUP72404A RS72404A RS 72404 A RS72404 A RS 72404A YU 72404 A YU72404 A YU 72404A YU P72404 A YUP72404 A YU P72404A RS 72404 A RS72404 A RS 72404A
- Authority
- RS
- Serbia
- Prior art keywords
- microorganism
- nucleotide sequence
- specific
- optionally
- expression
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title abstract 9
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 5
- 125000003729 nucleotide group Chemical group 0.000 abstract 5
- 230000004913 activation Effects 0.000 abstract 3
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 210000000172 cytosol Anatomy 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/16—Exonucleases active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters (3.16)
- C12Y301/16001—Spleen exonuclease (3.1.16.1), i.e. 5->3 exoribonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Abstract
Pronalazak se odnosi na obavijeni mikroorganizam u čiji genom su ubačene i mogu i mogu biti eksprimirane sledeće komponente: I) nukleotidna sekvenca koja kodira proizvod ekspresije, koji deluje direktno ili indirektno, antiproliferativno ili citotoksično, ili više različitih takvih proizvoda ekspresije, II) nukleotidna sekvenca koja kodira protein krvne plazme pod kontrolom aktivirajuće sekvence, koja se može aktivirati u mikroorganizmu, ili je konstitutivno aktivna, III) opcionalno, nukleotidna sekvenca koja kodira citospecifični ligand pod kontrolom aktivirajuće sekvence koja se može aktivirati u mikroorganizmu, ili je konstitutivno aktivna, IV) nukleotidna sekvenca za transportni sistem koji izaziva ekspresiju proizvoda ekspresije komponenata I) i II) kao i, opcionalno, III) na spoljnoj površini mikroorganizma ili sekreciju proizvoda ekspresije komponente I) i ekspresiju komponente II) kao i, opcionalno, III, i koja je, poželjno, konstitutivno aktivna, V) opcionalno, nukleotidna sekvenca za protein za lizu mikroorganizma u citosolu ćelija sisara i za intracelularno oslobađanje plazmida sa najmanje jednom ili više komponenti I) i VI sadržanih u liziranom mikroorganizmu, i VI) aktivirajuća sekvenca, koja se može aktivirati u mikroorganizmu, i/ili aktivirajuća sekvenca specifična za ćelije tkiva, ćelije tumora, funkcionalno specifična ili ne citospecifična, za ekspresiju komponente I), pri čemu svaka od komponenta I do VI, može biti jednostavno ili složeno, isto ili različito uređena.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10206325A DE10206325A1 (de) | 2002-02-14 | 2002-02-14 | Ummantelter Mikroorganismus |
| PCT/DE2003/000470 WO2003068954A2 (de) | 2002-02-14 | 2003-02-13 | Mikroorganismus zur gentherapeutischen behandlung proliferativer erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS72404A true RS72404A (en) | 2006-12-15 |
Family
ID=27674670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU72404A RS72404A (en) | 2002-02-14 | 2003-02-13 | Microorganism for genetic therapeutic treatment of proliferative diseases |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050244374A1 (sr) |
| EP (1) | EP1474519A2 (sr) |
| JP (1) | JP2005517405A (sr) |
| KR (1) | KR20040103941A (sr) |
| CN (1) | CN1646693A (sr) |
| AU (1) | AU2003206663B2 (sr) |
| BR (1) | BRPI0307722A2 (sr) |
| CA (1) | CA2513198A1 (sr) |
| DE (2) | DE10206325A1 (sr) |
| HR (1) | HRP20040832A2 (sr) |
| IL (1) | IL163553A0 (sr) |
| MX (1) | MXPA04007934A (sr) |
| NO (1) | NO20043800L (sr) |
| NZ (1) | NZ535310A (sr) |
| PL (1) | PL372901A1 (sr) |
| RS (1) | RS72404A (sr) |
| RU (1) | RU2004127459A (sr) |
| WO (1) | WO2003068954A2 (sr) |
| ZA (1) | ZA200407358B (sr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008504822A (ja) * | 2004-06-29 | 2008-02-21 | アンチキャンサー インコーポレーテッド | 癌選択的栄養要求株 |
| CN112423785A (zh) | 2018-07-19 | 2021-02-26 | 瑞泽恩制药公司 | 双特异性抗BCMAx抗CD3抗体及其用途 |
| US11519007B2 (en) | 2019-02-22 | 2022-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19720761A1 (de) * | 1997-05-07 | 1998-11-12 | Schering Ag | Verfahren zur Synthese und Sekretion von zur Kontrazeption geeigneter Proteine oder Proteinfragmente durch attenuierte Salmonellen oder einen anderen Gram-negativen attenuierten Impfstamm zur Erzeugung einer oralen Vakzinierung |
-
2002
- 2002-02-14 DE DE10206325A patent/DE10206325A1/de not_active Ceased
-
2003
- 2003-02-13 MX MXPA04007934A patent/MXPA04007934A/es not_active Application Discontinuation
- 2003-02-13 JP JP2003568069A patent/JP2005517405A/ja active Pending
- 2003-02-13 EP EP03704314A patent/EP1474519A2/de not_active Withdrawn
- 2003-02-13 KR KR10-2004-7012866A patent/KR20040103941A/ko not_active Application Discontinuation
- 2003-02-13 RS YU72404A patent/RS72404A/sr unknown
- 2003-02-13 CA CA002513198A patent/CA2513198A1/en not_active Abandoned
- 2003-02-13 RU RU2004127459/13A patent/RU2004127459A/ru unknown
- 2003-02-13 BR BRPI0307722A patent/BRPI0307722A2/pt not_active IP Right Cessation
- 2003-02-13 WO PCT/DE2003/000470 patent/WO2003068954A2/de active Application Filing
- 2003-02-13 CN CNA038082446A patent/CN1646693A/zh active Pending
- 2003-02-13 AU AU2003206663A patent/AU2003206663B2/en not_active Ceased
- 2003-02-13 NZ NZ535310A patent/NZ535310A/en unknown
- 2003-02-13 DE DE2003190506 patent/DE10390506D2/de not_active Expired - Lifetime
- 2003-02-13 PL PL03372901A patent/PL372901A1/xx not_active Application Discontinuation
- 2003-02-13 US US10/504,944 patent/US20050244374A1/en not_active Abandoned
- 2003-08-13 IL IL16355303A patent/IL163553A0/xx unknown
-
2004
- 2004-09-10 NO NO20043800A patent/NO20043800L/no not_active Application Discontinuation
- 2004-09-14 ZA ZA200407358A patent/ZA200407358B/xx unknown
- 2004-09-14 HR HRP20040832 patent/HRP20040832A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003206663B2 (en) | 2007-11-01 |
| KR20040103941A (ko) | 2004-12-09 |
| AU2003206663A1 (en) | 2003-09-04 |
| CA2513198A1 (en) | 2003-08-21 |
| DE10206325A1 (de) | 2003-09-04 |
| BRPI0307722A2 (pt) | 2017-07-04 |
| JP2005517405A (ja) | 2005-06-16 |
| WO2003068954A3 (de) | 2003-10-16 |
| US20050244374A1 (en) | 2005-11-03 |
| EP1474519A2 (de) | 2004-11-10 |
| MXPA04007934A (es) | 2005-11-23 |
| HRP20040832A2 (en) | 2004-12-31 |
| NZ535310A (en) | 2008-04-30 |
| RU2004127459A (ru) | 2005-05-10 |
| PL372901A1 (en) | 2005-08-08 |
| WO2003068954A8 (de) | 2005-10-13 |
| DE10390506D2 (de) | 2005-01-13 |
| AU2003206663B9 (en) | 2003-09-04 |
| WO2003068954A2 (de) | 2003-08-21 |
| CN1646693A (zh) | 2005-07-27 |
| ZA200407358B (en) | 2005-11-18 |
| IL163553A0 (en) | 2005-12-18 |
| NO20043800L (no) | 2004-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Margottin et al. | Participation of the TATA factor in transcription of the yeast U6 gene by RNA polymerase C | |
| Lefrère et al. | Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study | |
| ATE323169T1 (de) | Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren | |
| MX9705039A (es) | Genes y proteinas de muerte celular programada. | |
| Jiang et al. | NF-κB p65 transactivation domain is involved in the NF-κB-inducing kinase pathway | |
| DE69834936D1 (de) | Vektor zur gewebespezifischen replikation und expression | |
| EP0935001A4 (en) | NEW VEGF-LIKE FACTORS | |
| HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| MX9708854A (es) | Terapia de genes para regulacion de celulas efectoras. | |
| GB2367555A (en) | Control of gene expression | |
| WO2003023000A3 (en) | Linear dna fragments for gene expression | |
| ZA200108414B (en) | Akt nucleic acids, polypeptides, and uses thereof. | |
| RS72404A (en) | Microorganism for genetic therapeutic treatment of proliferative diseases | |
| AU2002364302A1 (en) | Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases | |
| Brakebusch et al. | Expression of the 90K immunostimulator gene is controlled by a promoter with unique features | |
| AU6349400A (en) | Methods for treatment of hyperproliferative diseases using human mda-7 | |
| WO2007089950A3 (en) | Preparations of growth hormone | |
| AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
| GB2350060A (en) | Nucleic acid delivery | |
| PL354747A1 (en) | Modified ubiquitin regulatory system | |
| WO2001025398A3 (en) | Process for inducing functional tolerance to gene transfer products | |
| EP0763205A4 (en) | NUCLEIC ACID SEQUENCES REGULATING THE EXPRESSION OF LUNG SPECIFIC GENES | |
| WO2004024867A3 (en) | Vigilant vector system | |
| AU2944100A (en) | Gene therapeutics | |
| WO2004049917A3 (en) | Methods of therapy and diagnosis using targeting of cells that express ly-9 |